RDiscovery invests into Eurus Therapeutics

Jun 27, 2025 — RDiscovery has made an investment in Eurus Therapeutics Co., Ltd. (headquartered in Fujisawa City, Kanagawa, Japan; CEO and Founder Takato Noumi, Ph.D.).

Eurus Therapeutics is dedicated to creating innovative therapies based on its proprietary genome-editing technology, which is independent of the CRISPR/Cas system.

RDiscovery supports Eurus’ technology and business development through its participation in the Board of Director meetings and other activities to increase the value of the novel genome editing technology, an innovation originating in Japan.

about company

Eurus Therapeutics is dedicated to creating innovative therapies based on its proprietary genome-editing technology, which is independent of the CRISPR/Cas system. By unlocking new possibilities in genome editing, we aim to bring new hope to patients facing inherited and life-threatening diseases.